

# CITATION REPORT

List of articles citing

**Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup**

**DOI: 10.1016/j.jalz.2011.05.2351**

**Alzheimer's and Dementia, 2011, 7, 367-85.**

**Source:** <https://exaly.com/paper-pdf/50444510/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
431	Amyloid imaging in the differential diagnosis of dementia: review and potential clinical applications. <b>2011</b> , 3, 31		67
430	Testing the right target and right drug at the right stage. <b>2011</b> , 3, 111cm33		366
429	News in brief: Biomedical briefing. <b>2011</b> , 17, 910-911		
428	Encephalopathy with amyloid angiopathy and numerous amyloid plaques with low levels of CSF A $\beta$ -40/A $\beta$ -42. <b>2012</b> , 19, 186-90		3
427	The neurobiology of Alzheimer disease defined by neuroimaging. <b>2012</b> , 25, 410-20		28
426	Dementia in 2011: Microbleeds in dementia--singing a different ARIA. <b>2012</b> , 8, 68-70		7
425	Reducing available soluble $\beta$ amyloid prevents progression of cerebral amyloid angiopathy in transgenic mice. <b>2012</b> , 71, 1009-17		8
424	Current world literature. <b>2012</b> , 25, 565-73		
423	Applications of imaging biomarkers in the early clinical development of central nervous system therapeutic agents. <b>2012</b> , 91, 315-20		11
422	Microvascular perfusion based on arterial spin labeled perfusion MRI as a measure of vascular risk in Alzheimer's disease. <b>2012</b> , 32, 677-87		18
421	Translational research in neurology: dementia. <b>2012</b> , 69, 969-77		10
420	Current insights into the pathophysiology of Alzheimer's disease: selecting targets for early therapeutic intervention. <b>2012</b> , 24 Suppl 1, S10-7		22
419	Amyloid-related imaging abnormalities associated with immunotherapy in Alzheimer's disease patients. <b>2012</b> , 7, 395-401		1
418	Drug Treatments in Development for Alzheimer's Disease. <b>2012</b> , 42, 58-65		4
417	The value and limitations of transgenic mouse models used in drug discovery for Alzheimer's disease: an update. <b>2012</b> , 7, 281-97		33
416	A plaque-specific antibody clears existing $\beta$ amyloid plaques in Alzheimer's disease mice. <b>2012</b> , 76, 908-20		186
415	Stealth attack: plaque-specific antibody allows for efficient A $\beta$ removal without side effects. <b>2012</b> , 76, 859-61		1

414	The epidemiology of Alzheimer's disease: laying the foundation for drug design, conduct, and analysis of clinical trials. <i>Alzheimer's and Dementia</i> , <b>2012</b> , 8, 237-42	1.2	22
413	Alzheimer mechanisms and therapeutic strategies. <b>2012</b> , 148, 1204-22		1278
412	Gantenerumab for the treatment of Alzheimer's disease. <b>2012</b> , 12, 1077-86		28
411	Clinical aspects of microbleeds in Alzheimer's disease. <b>2012</b> , 322, 56-8		17
410	Alzheimer's-related peptide amyloid- $\beta$ plays a conserved role in angiogenesis. <b>2012</b> , 7, e39598		31
409	Targeting Beta amyloid: a clinical review of immunotherapeutic approaches in Alzheimer's disease. <b>2012</b> , 2012, 628070		55
408	Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play. <b>2012</b> , 263, 344-61		166
407	Task force on Alzheimer's disease trial methodology: recruitment and retention, data management and analysis. The use of imaging in recruitment: maintenance and methodological issues in Alzheimer's trials. <b>2012</b> , 16, 349-51		
406	Alzheimer's disease therapeutic trials: EU/US Task Force report on recruitment, retention, and methodology. <b>2012</b> , 16, 339-45		31
405	'Clinical trials in Alzheimer's disease': immunotherapy approaches. <b>2012</b> , 120 Suppl 1, 186-193		105
404	Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. <b>2012</b> , 11, 241-9		307
403	ARIA from off-key operas?. <b>2012</b> , 11, 207-8		4
402	Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors. <b>2012</b> , 134, 8-25		153
401	Neuroimaging results impose new views on Alzheimer's disease--the role of amyloid revised. <b>2012</b> , 45, 153-72		38
400	Neuroprotective effects of D-Ala(2)GIP on Alzheimer's disease biomarkers in an APP/PS1 mouse model. <b>2013</b> , 5, 20		49
399	Treatment of Alzheimer's Disease: Current Management and Experimental Therapeutics. <b>2013</b> , 2, 174-181		7
398	New and different approaches needed for the design and execution of Alzheimer's clinical trials. <i>Alzheimer's and Dementia</i> , <b>2013</b> , 9, 436-7	1.2	2
397	MR imaging features of amyloid-related imaging abnormalities. <b>2013</b> , 34, 1958-65		32

396	Alzheimer's disease drug development: translational neuroscience strategies. <b>2013</b> , 18, 128-38		22
395	Improving Alzheimer's disease phase II clinical trials. <i>Alzheimer's and Dementia</i> , <b>2013</b> , 9, 39-49	1.2	24
394	Clinical trials of amyloid-based immunotherapy for Alzheimer's disease: end of beginning or beginning of end?. <b>2013</b> , 13, 1515-22		16
393	Non-pharmacological interventions and neuroplasticity in early stage Alzheimer's disease. <b>2013</b> , 13, 1235-45		34
392	Immunomodulation targeting of both A $\beta$ and tau pathological conformers ameliorates Alzheimer's disease pathology in TgSwDI and 3xTg mouse models. <b>2013</b> , 10, 150		36
391	Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. <b>2013</b> , 12, 822-38		2662
390	Top 20 articles cited from Alzheimer's & Dementia since 2008. <i>Alzheimer's and Dementia</i> , <b>2013</b> , 9, 619-21.1,2		
389	Amyloid beta immunization worsens iron deposits in the choroid plexus and cerebral microbleeds. <b>2013</b> , 34, 2613-22		26
388	Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. <b>2013</b> , 12, 233-43		146
387	Vascular alterations in PDAPP mice after anti-A $\beta$ immunotherapy: Implications for amyloid-related imaging abnormalities. <i>Alzheimer's and Dementia</i> , <b>2013</b> , 9, S105-15	1.2	44
386	Amyloid PET in clinical practice: Its place in the multidimensional space of Alzheimer's disease. <b>2013</b> , 2, 497-511		74
385	Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. <b>2013</b> , 169, 737-43		104
384	Focal hemosiderin deposits and $\beta$ amyloid load in the ADNI cohort. <i>Alzheimer's and Dementia</i> , <b>2013</b> , 9, S116-23	1.2	50
383	Research and standardization in Alzheimer's trials: reaching international consensus. <i>Alzheimer's and Dementia</i> , <b>2013</b> , 9, 160-8	1.2	16
382	Specific risk factors for microbleeds and white matter hyperintensities in Alzheimer's disease. <b>2013</b> , 34, 2488-94		59
381	An MRI rating scale for amyloid-related imaging abnormalities with edema or effusion. <b>2013</b> , 34, 1550-5		24
380	Neurosteroids as regenerative agents in the brain: therapeutic implications. <b>2013</b> , 9, 241-50		114
379	Can we prevent Alzheimer's disease? Secondary "prevention" trials in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2013</b> , 9, 123-131.e1	1.2	82

378	Developing therapeutic antibodies for neurodegenerative disease. <b>2013</b> , 10, 459-72	128
377	Induction of hyperhomocysteinemia models vascular dementia by induction of cerebral microhemorrhages and neuroinflammation. <b>2013</b> , 33, 708-15	105
376	Anti-amyloid autoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapies. <b>2013</b> , 73, 449-58	111
375	Bapineuzumab and solanezumab for Alzheimer's disease: is the 'amyloid cascade hypothesis' still alive?. <b>2013</b> , 13, 1075-84	83
374	Cerebral microbleeds: a guide to detection and clinical relevance in different disease settings. <b>2013</b> , 55, 655-74	59
373	Treating Alzheimer's disease with monoclonal antibodies: current status and outlook for the future. <b>2013</b> , 5, 56	36
372	A conceptual framework and ethics analysis for prevention trials of Alzheimer Disease. <b>2013</b> , 110, 114-23	19
371	Inflammatory components in human Alzheimer's disease and after active amyloid- $\beta$ 2 immunization. <b>2013</b> , 136, 2677-96	165
370	Neuroimaging and the search for a cure for Alzheimer disease. <b>2013</b> , 269, 671-91	37
369	Cortical superficial siderosis and intracerebral hemorrhage risk in cerebral amyloid angiopathy. <b>2013</b> , 81, 1666-73	106
368	Inflammation in Alzheimer's disease: insights from immunotherapy. <b>2013</b> , 136, 2654-6	33
367	Intracranial injection of Gammagard, a human IVIg, modulates the inflammatory response of the brain and lowers A $\beta$ in APP/PS1 mice along a different time course than anti-A $\beta$ antibodies. <b>2013</b> , 33, 9684-92	53
366	Inflammatory cerebral amyloid angiopathy and amyloid-modifying therapies: variations on the same ARIA?. <b>2013</b> , 73, 439-41	17
365	Brain and circulating levels of A $\beta$ -40 differentially contribute to vasomotor dysfunction in the mouse brain. <b>2013</b> , 44, 198-204	42
364	Positron emission tomography with [18F]flutemetamol and [11C]PiB for in vivo detection of cerebral cortical amyloid in normal pressure hydrocephalus patients. <b>2013</b> , 20, 1043-52	33
363	Biomarker-driven therapeutic management of Alzheimer's disease: establishing the foundations. <b>2014</b> , 95, 67-77	17
362	Chronic rapamycin restores brain vascular integrity and function through NO synthase activation and improves memory in symptomatic mice modeling Alzheimer's disease. <b>2013</b> , 33, 1412-21	137
361	Preclinical Alzheimer disease-the challenges ahead. <b>2013</b> , 9, 54-8	177

360	Bapineuzumab alters amyloid composition: implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy. <b>2013</b> , 8, e59735	26
359	Imaging of cerebrovascular pathology in animal models of Alzheimer's disease. <b>2014</b> , 6, 32	58
358	Frontiers in therapeutic development of allopregnanolone for Alzheimer's disease and other neurological disorders. <b>2014</b> , 8, 203	47
357	Cerebral microbleeds: a review of clinical, genetic, and neuroimaging associations. <b>2014</b> , 4, 205	140
356	Efficacy and safety studies of gantenerumab in patients with Alzheimer's disease. <b>2014</b> , 14, 973-86	33
355	Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward. <b>2014</b> , 10, 405-19	70
354	Amyloid-directed immunotherapy for Alzheimer's disease. <b>2014</b> , 275, 284-95	106
353	Spontaneous amyloid-related imaging abnormalities in a cognitively normal adult. <b>2014</b> , 83, 1771-2	4
352	Aβ immunotherapy for Alzheimer's disease: effects on apoE and cerebral vasculopathy. <b>2014</b> , 128, 777-89	32
351	Imaging endpoints for clinical trials in Alzheimer's disease. <b>2014</b> , 6, 87	40
350	Neuroimaging of therapy-associated brain tissue abnormalities. <b>2014</b> , 27, 380-9	5
349	Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?. <b>2014</b> , 27, 128-37	76
348	Visit-to-visit blood pressure variability in Alzheimer disease. <b>2014</b> , 28, 347-51	44
347	Parallel discovery of Alzheimer's therapeutics. <b>2014</b> , 6, 241-5	34
346	Incidence of cerebral microbleeds in preclinical Alzheimer disease. <b>2014</b> , 82, 1266-73	110
345	Allopregnanolone as regenerative therapeutic for Alzheimer's disease: translational development and clinical promise. <b>2014</b> , 113, 40-55	73
344	Blood pressure variability predicts cognitive decline in Alzheimer's disease patients. <b>2014</b> , 35, 2282-7	52
343	A raging fire in acute lacunar stroke: inflammation, blood-brain barrier dysfunction and the origin of cerebral microbleeds. <b>2014</b> , 340, 1-2	10

342	Building a pipeline to discover and validate novel therapeutic targets and lead compounds for Alzheimer's disease. <b>2014</b> , 88, 617-30		32
341	Active immunotherapy options for Alzheimer's disease. <b>2014</b> , 6, 7		58
340	Microbleeds in the logopenic variant of primary progressive aphasia. <i>Alzheimer's and Dementia</i> , <b>2014</b> , 10, 62-6	1.2	9
339	What is normal in normal aging? Effects of aging, amyloid and Alzheimer's disease on the cerebral cortex and the hippocampus. <b>2014</b> , 117, 20-40		412
338	Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. <b>2014</b> , 370, 311-21		1098
337	Choosing Alzheimer's disease prevention clinical trial populations. <b>2014</b> , 35, 466-71		12
336	Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. <b>2014</b> , 370, 322-33		1274
335	Editorial. <i>Alzheimer's and Dementia</i> , <b>2014</b> , 10, 590-1	1.2	
334	Open questions for Alzheimer's disease immunotherapy. <b>2014</b> , 6, 3		59
333	Blocking the apoE/A $\beta$ interaction ameliorates A $\beta$ -related pathology in APOE $\epsilon$ and $\epsilon$ targeted replacement Alzheimer model mice. <b>2014</b> , 2, 75		32
332	Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?. <b>2014</b> , 14, 1465-76		50
331	Cerebral microbleeds in a multiethnic elderly community: demographic and clinical correlates. <b>2014</b> , 345, 125-30		25
330	Clinical trial of an inhibitor of RAGE-A $\beta$ interactions in Alzheimer disease. <b>2014</b> , 82, 1536-42		131
329	Acute stroke syndromes caused by small vessel disease. 217-235		
328	Interaction between cerebral small vessel disease and neurodegenerative changes. 298-310		
327	How can we improve transfer of outcomes from randomized clinical trials to clinical practice with disease-modifying drugs in Alzheimer's disease?. <b>2014</b> , 13, 197-9		3
326	Murine versus human apolipoprotein E4: differential facilitation of and co-localization in cerebral amyloid angiopathy and amyloid plaques in APP transgenic mouse models. <b>2015</b> , 3, 70		31
325	Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease. <b>2016</b> , 49, 1123-34		24

324	Alzheimer Lesions in the Autopsied Brains of People 30 to 50 Years of Age. <b>2015</b> , 28, 144-52		26
323	Multiple Spontaneous Cerebral Microbleeds and Leukoencephalopathy in PSEN1-Associated Familial Alzheimer's Disease: Mirror of Cerebral Amyloid Angiopathy?. <b>2015</b> , 47, 535-8		4
322	Anti-A $\beta$ Autoantibodies in Amyloid Related Imaging Abnormalities (ARIA): Candidate Biomarker for Immunotherapy in Alzheimer's Disease and Cerebral Amyloid Angiopathy. <b>2015</b> , 6, 207		36
321	First administration of the Fc-attenuated anti-A $\beta$ amyloid antibody GSK933776 to patients with mild Alzheimer's disease: a randomized, placebo-controlled study. <b>2015</b> , 10, e0098153		20
320	News from the AAN Annual Meeting. <b>2015</b> , 15, 32-34		
319	Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer's disease treated with bapineuzumab: a historical, prospective secondary analysis. <b>2016</b> , 87, 106-12		23
318	Computer-aided detection of cerebral microbleeds in susceptibility-weighted imaging. <b>2015</b> , 46 Pt 3, 269-76		24
317	APOE-modulated A $\beta$ induced neuroinflammation in Alzheimer's disease: current landscape, novel data, and future perspective. <b>2015</b> , 133, 465-88		98
316	Microbleeds in atypical presentations of Alzheimer's disease: a comparison to dementia of the Alzheimer's type. <b>2015</b> , 45, 1109-17		12
315	Cerebral amyloid angiopathy-related atraumatic convexal subarachnoid hemorrhage: an ARIA before the tsunami. <b>2015</b> , 35, 710-7		30
314	Frequency and topography of cerebral microbleeds in dementia with Lewy bodies compared to Alzheimer's disease. <b>2015</b> , 21, 1101-4		18
313	Cortical superficial siderosis: detection and clinical significance in cerebral amyloid angiopathy and related conditions. <b>2015</b> , 138, 2126-39		208
312	Prevention studies in Alzheimer's disease: progress towards the development of new therapeutics. <b>2015</b> , 29, 519-28		5
311	Perspective: The Alzheimer's Disease Neuroimaging Initiative and the role and contributions of the Private Partner Scientific Board (PPSB). <i>Alzheimer's and Dementia</i> , <b>2015</b> , 11, 840-9	1.2	8
310	Genetic determinants of white matter hyperintensities and amyloid angiopathy in familial Alzheimer's disease. <b>2015</b> , 36, 3140-3151		46
309	Re-evaluation of the Blood-Brain Barrier in the Presence of Alzheimer's Disease Pathology. <b>2015</b> , 88, 237-9		17
308	The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability in longitudinal data. <i>Alzheimer's and Dementia</i> , <b>2015</b> , 11, 1050-68	1.2	79
307	[A subacute dementia: Inflammatory cerebral amyloid angiopathy]. <b>2015</b> , 171, 832-40		



306	Modulators of Amyloid Protein (A $\beta$ ) Self-Assembly. <b>2016</b> , 97-191	5
305	In Vivo Detection of Amyloid Plaques by Gadolinium-Stained MRI Can Be Used to Demonstrate the Efficacy of an Anti-amyloid Immunotherapy. <b>2016</b> , 8, 55	13
304	Magnetic Resonance Imaging to Detect Early Molecular and Cellular Changes in Alzheimer's Disease. <b>2016</b> , 8, 139	23
303	Targeting microglia for the treatment of Alzheimer's Disease. <b>2016</b> , 64, 1710-32	113
302	Amyloid-Related Imaging Abnormalities (ARIA) in Immunotherapy Trials for Alzheimer's Disease: Need for Prognostic Biomarkers?. <b>2016</b> , 52, 417-20	33
301	Immunotherapeutic strategies: a wide range of approaches for Alzheimer's disease treatment. <b>2016</b> , 18, e13	26
300	Orexin and Alzheimer's Disease. <b>2017</b> , 33, 305-322	31
299	Monitoring Blood-Brain Barrier Integrity Following Amyloid- $\beta$ Immunotherapy Using Gadolinium-Enhanced MRI in a PDAPP Mouse Model. <b>2016</b> , 54, 723-35	15
298	Long-term safety and tolerability of bapineuzumab in patients with Alzheimer's disease in two phase 3 extension studies. <b>2016</b> , 8, 24	15
297	Diagnostic et prise en charge d'une angiopathie amyloïde cérébrale sporadique. <b>2016</b> , 7, 239-249	0
296	Cerebral Amyloid Angiopathy-Related Inflammation Biomarkers: Where are we Now?. <b>2016</b> , 50, 9-11	1
295	Clinical trials in Alzheimer's disease. <b>2016</b> , 153-172	
294	Longitudinal noninvasive magnetic resonance imaging of brain microhemorrhages in BACE inhibitor-treated APP transgenic mice. <b>2016</b> , 45, 50-60	11
293	Amyloid status imputed from a multimodal classifier including structural MRI distinguishes progressors from nonprogressors in a mild Alzheimer's disease clinical trial cohort. <i>Alzheimer's and Dementia</i> , <b>2016</b> , 12, 977-986	1.2 18
292	Demonstration of safety of intravenous immunoglobulin in geriatric patients in a long-term, placebo-controlled study of Alzheimer's disease. <b>2016</b> , 2, 131-139	2
291	Prefrontal contributions to relational encoding in amnesic mild cognitive impairment. <b>2016</b> , 11, 158-166	5
290	Reduced Efficacy of Anti-A $\beta$ Immunotherapy in a Mouse Model of Amyloid Deposition and Vascular Cognitive Impairment Comorbidity. <b>2016</b> , 36, 9896-907	22
289	Advances in neuroimaging in frontotemporal dementia. <b>2016</b> , 138 Suppl 1, 193-210	52

288	Alzheimer's disease: Attack on amyloid- $\beta$ protein. <b>2016</b> , 537, 36-7	37
287	The antibody aducanumab reduces A $\beta$ plaques in Alzheimer's disease. <b>2016</b> , 537, 50-6	1419
286	Microbleeds in Alzheimer's Disease: A Neuropsychological Overview and Meta-Analysis. <b>2016</b> , 43, 753-759	9
285	Genetic and degenerative disorders primarily causing dementia. <b>2016</b> , 135, 525-564	3
284	Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials. <b>2016</b> , 8, 18	148
283	Type 2 Diabetes, Obesity, and Risk for Dementia: Recent Insights into Brain Insulin Resistance and Hypometabolism. <b>2016</b> , 3, 293-300	3
282	Volumetric MRI as a Diagnostic Tool in Alzheimer's Disease. <b>2016</b> , 181-198	2
281	Symptomatic Cognitive Enhancing Agents. <b>2016</b> , 459-475	3
280	Immunotherapy Against Amyloid- $\beta$ in Alzheimer's Disease: An Overview. <b>2016</b> , 3-17	1
279	Active Immunization Against the Amyloid- $\beta$ Peptide. <b>2016</b> , 19-35	
278	Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer's disease. <b>2016</b> , 2, 75-85	18
277	First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer's disease. <b>2016</b> , 8, 12	29
276	Safety and tolerability of BAN2401--a clinical study in Alzheimer's disease with a protofibril selective A $\beta$ antibody. <b>2016</b> , 8, 14	104
275	High-affinity Anticalins with aggregation-blocking activity directed against the Alzheimer's amyloid peptide. <b>2016</b> , 473, 1563-78	22
274	Brain neural synchronization and functional coupling in Alzheimer's disease as revealed by resting state EEG rhythms. <b>2016</b> , 103, 88-102	161
273	Cerebral microbleeds as a biomarker in Alzheimer's disease? A review in the field. <b>2016</b> , 10, 9-18	20
272	Default mode network connectivity is linked to cognitive functioning and CSF A $\beta$ -42 levels in Alzheimer's disease. <b>2016</b> , 62, 125-32	14
271	Neuroimaging in Alzheimer's disease: preclinical challenges toward clinical efficacy. <b>2016</b> , 175, 37-53	5

270	Neuroimaging biomarkers in Alzheimer's disease and other dementias. <b>2016</b> , 30, 4-16	27
269	Alzheimer's disease. <b>2016</b> , 388, 505-17	1720
268	Cerebral amyloid angiopathy-related inflammation: A potentially reversible cause of dementia with characteristic imaging findings. <b>2016</b> , 43, 11-7	6
267	Validation of an MRI Rating Scale for Amyloid-Related Imaging Abnormalities. <b>2017</b> , 27, 318-325	6
266	Comparison of cerebrospinal fluid profiles in Alzheimer's disease with multiple cerebral microbleeds and cerebral amyloid angiopathy-related inflammation. <b>2017</b> , 264, 373-381	8
265	Upregulated Expression of Heparanase and Heparanase 2 in the Brains of Alzheimer's Disease. <b>2017</b> , 58, 185-192	27
264	Neural changes in Alzheimer's disease from circuit to molecule: Perspective of optogenetics. <b>2017</b> , 79, 110-118	8
263	Immunomodulation via Toll-like Receptor 9: An Adjunct Therapy Strategy against Alzheimer's Disease?. <b>2017</b> , 37, 4864-4867	4
262	Translational Research: Preclinical to Healthy Volunteer to Patient. <b>2017</b> , 341-372	1
261	Clinical Amyloid Imaging. <b>2017</b> , 47, 31-43	44
260	A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Oral ELND005 (scyllo-Inositol) in Young Adults with Down Syndrome without Dementia. <b>2017</b> , 58, 401-411	22
259	Alzheimer's disease drug development pipeline: 2017. <b>2017</b> , 3, 367-384	256
258	A phase 3 trial of IV immunoglobulin for Alzheimer disease. <b>2017</b> , 88, 1768-1775	99
257	Cerebral microhemorrhages: mechanisms, consequences, and prevention. <b>2017</b> , 312, H1128-H1143	63
256	Recent Progress in Alzheimer's Disease Research, Part 3: Diagnosis and Treatment. <b>2017</b> , 57, 645-665	76
255	Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer's Disease Patients. <b>2017</b> , 57, 557-573	30
254	The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement. <i>Alzheimer's and Dementia</i> , <b>2017</b> , 13, 561-571	1.2 137
253	The increasing impact of cerebral amyloid angiopathy: essential new insights for clinical practice. <b>2017</b> , 88, 982-994	109

252	Towards the improvement in stability of an anti-A $\beta$ single-chain variable fragment, scFv-h3D6, as a way to enhance its therapeutic potential. <b>2017</b> , 24, 167-175	8
251	APOE Genotype Differentially Modulates Effects of Anti-A $\beta$ Passive Immunization in APP Transgenic Mice. <b>2017</b> , 12, 12	15
250	Multiple comorbid neuropathologies in the setting of Alzheimer's disease neuropathology and implications for drug development. <b>2017</b> , 3, 83-91	57
249	Efficacy and safety of anti-amyloid- immunotherapy for Alzheimer's disease: a systematic review and network meta-analysis. <b>2017</b> , 4, 931-942	36
248	[A bioactive implantable device to prevent Alzheimer's disease]. <b>2017</b> , 33, 81-84	1
247	Classification of Healthy Subjects and Alzheimer's Disease Patients with Dementia from Cortical Sources of Resting State EEG Rhythms: A Study Using Artificial Neural Networks. <b>2016</b> , 10, 604	35
246	Amyloid-Related Imaging Abnormalities in an Aged Squirrel Monkey with Cerebral Amyloid Angiopathy. <b>2017</b> , 57, 519-530	12
245	Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-APP <sup>swe</sup> Mice Without Inducing Microhemorrhage. <b>2017</b> , 59, 1393-1413	18
244	Primary and Secondary Prevention Trials in Alzheimer Disease: Looking Back, Moving Forward. <b>2017</b> , 14, 426-440	42
243	The past, present, and future of disease-modifying therapies for Alzheimer's disease. <b>2017</b> , 93, 757-771	24
242	Encephalopathy. <b>2018</b> , 553-590	
241	Clinical Trials for Disease-Modifying Therapies in Alzheimer's Disease: A Primer, Lessons Learned, and a Blueprint for the Future. <b>2018</b> , 64, S3-S22	74
240	Sifting through a failed Alzheimer trial: What biomarkers tell us about what happened. <b>2018</b> , 90, 447-448	2
239	Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab. <b>2018</b> , 90, e877-e886	15
238	Diagnosis of Cerebral Amyloid Angiopathy: Evolution of the Boston Criteria. <b>2018</b> , 49, 491-497	185
237	Immunotherapy for neurodegenerative diseases: the Alzheimer's disease paradigm. <b>2018</b> , 19, 59-67	5
236	The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's disease, including a placebo-treated noncarrier cohort. <b>2018</b> , 4, 150-160	73
235	The value of subtraction MRI in detection of amyloid-related imaging abnormalities with oedema or effusion in Alzheimer's patients: An interobserver study. <b>2018</b> , 28, 1215-1226	6

234	Anti-Amyloid- $\beta$ Monoclonal Antibodies for Alzheimer's Disease: Pitfalls and Promise. <b>2018</b> , 83, 311-319	271
233	Advances in developing novel therapeutic strategies for Alzheimer's disease. <b>2018</b> , 13, 64	116
232	SAR228810: an antibody for protofibrillar amyloid $\beta$ peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA). <b>2018</b> , 10, 117	12
231	Passive Immunotherapies for Central Nervous System Disorders: Current Delivery Challenges and New Approaches. <b>2018</b> , 29, 3937-3966	15
230	Secondary prevention of Alzheimer's dementia: neuroimaging contributions. <b>2018</b> , 10, 112	27
229	Passive A $\beta$ Immunotherapy: Current Achievements and Future Perspectives. <b>2018</b> , 23,	29
228	Passive Immunotherapy in Alzheimer's Disease. <b>2018</b> ,	2
227	PET/CT of Dementia. <b>2018</b> , 211, 246-259	11
226	Subtle Alterations in Spatial Memory Induced by Amyloid Peptides Infusion in Rats. <b>2018</b> , 10, 18	3
225	Targeting Beta-Amyloid at the CSF: A New Therapeutic Strategy in Alzheimer's Disease. <b>2018</b> , 10, 100	12
224	MRI Characterizes the Progressive Course of AD and Predicts Conversion to Alzheimer's Dementia 24 Months Before Probable Diagnosis. <b>2018</b> , 10, 135	30
223	Antibody Engineering for Optimized Immunotherapy in Alzheimer's Disease. <b>2018</b> , 12, 254	11
222	An in vitro paradigm to assess potential anti-A $\beta$ antibodies for Alzheimer's disease. <b>2018</b> , 9, 2676	26
221	A Randomized Phase 2 Study of an Anti-Amyloid $\beta$ Monoclonal Antibody in Geographic Atrophy Secondary to Age-Related Macular Degeneration. <b>2018</b> , 2, 1028-1040	30
220	Recent advancements toward therapeutic vaccines against Alzheimer's disease. <b>2018</b> , 17, 707-721	29
219	Inhaled Xenon Washout as a Biomarker of Alzheimer's Disease. <b>2018</b> , 8,	10
218	Safety, tolerability and immunogenicity of an active anti-A $\beta$ vaccine (ABvac40) in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase I trial. <b>2018</b> , 10, 12	33
217	Safety and efficacy of focused ultrasound induced blood-brain barrier opening, an integrative review of animal and human studies. <b>2019</b> , 309, 25-36	40

216	Blood-brain barrier and innate immunity in the pathogenesis of Alzheimer's disease. <b>2019</b> , 168, 99-145	17
215	A Rationally Designed Humanized Antibody Selective for Amyloid Beta Oligomers in Alzheimer's Disease. <b>2019</b> , 9, 9870	19
214	Anti-A $\beta$ Antibodies and Cerebral Amyloid Angiopathy Complications. <b>2019</b> , 10, 1534	13
213	Slightly Symptomatic Cerebral Amyloid Angiopathy-Related Inflammation with Spontaneous Remission in Four Months. <b>2019</b> , 2019, 5308208	2
212	Early A $\beta$ reduction prevents progression of cerebral amyloid angiopathy. <b>2019</b> , 86, 561-571	15
211	Applications of Neuroimaging Biomarkers in CNS Drug Development. <b>2019</b> , 115-158	
210	Heterogeneity in Cost-Effectiveness Analysis of Vaccination for Mild and Moderate Alzheimer's Disease. <b>2019</b> , 16, 495-504	
209	Identification of prognostic factors to predict cognitive decline of patients with early Alzheimer's disease in the Japanese Alzheimer's Disease Neuroimaging Initiative study. <b>2019</b> , 5, 364-373	6
208	The "rights" of precision drug development for Alzheimer's disease. <b>2019</b> , 11, 76	93
207	The $\beta$ secretase (BACE) inhibitor NB-360 in preclinical models: From amyloid- $\beta$ reduction to downstream disease-relevant effects. <b>2019</b> , 176, 3435-3446	11
206	Pharmacokinetic parameters and mechanism of action of an efficient anti-A $\beta$ single chain antibody fragment. <b>2019</b> , 14, e0217793	8
205	Q $\beta$ Virus-like particle-based vaccine induces robust immunity and protects against tauopathy. <b>2019</b> , 4, 26	22
204	Persistent neuropathological effects 14 years following amyloid- $\beta$ immunization in Alzheimer's disease. <b>2019</b> , 142, 2113-2126	74
203	Blood Pressure Control and Protection of the Aging Brain. <b>2019</b> , 16, 569-579	8
202	Texture descriptors and voxels for the early diagnosis of Alzheimer's disease. <b>2019</b> , 97, 19-26	20
201	Immunotherapy with ponezumab for probable cerebral amyloid angiopathy. <b>2019</b> , 6, 795-806	30
200	Intravenous Immunoglobulin for Patients With Alzheimer's Disease: A Systematic Review and Meta-Analysis. <b>2019</b> , 34, 281-289	5
199	The Role of Biomarkers in Alzheimer's Disease Drug Development. <b>2019</b> , 1118, 29-61	40

198	The amyloid cascade and Alzheimer's disease therapeutics: theory versus observation. <b>2019</b> , 99, 958-970	50
197	An Integrated View on Vascular Dysfunction in Alzheimer's Disease. <b>2019</b> , 19, 109-127	30
196	Characterization of the selective in vitro and in vivo binding properties of crenezumab to oligomeric A $\beta$ <b>2019</b> , 11, 97	4
195	Early onset cerebral amyloid angiopathy following childhood exposure to cadaveric dura. <b>2019</b> , 85, 284-290	32
194	Cerebral Amyloid Angiopathy and Neuritic Plaque Pathology Correlate with Cognitive Decline in Elderly Non-Demented Individuals. <b>2019</b> , 67, 411-422	6
193	Cerebral microbleeds: Prevalence and relationship to amyloid burden. <b>2019</b> , 92, e253-e262	31
192	Sleep and circadian rhythm disruption and stress intersect in Alzheimer's disease. <b>2019</b> , 10, 100133	24
191	Revisiting the intersection of amyloid, pathologically modified tau and iron in Alzheimer's disease from a ferroptosis perspective. <b>2020</b> , 184, 101716	49
190	The path forward in Alzheimer's disease therapeutics: Reevaluating the amyloid cascade hypothesis. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, 1553-1560	1.2 72
189	Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways. <b>2020</b> , 16, 30-42	171
188	Alzheimer's disease: Recent treatment strategies. <b>2020</b> , 887, 173554	95
187	SPECT imaging of distribution and retention of a brain-penetrating bispecific amyloid- $\beta$ antibody in a mouse model of Alzheimer's disease. <b>2020</b> , 9, 37	18
186	Diagnostic and Prognostic Laboratory Testing for Alzheimer Disease. <b>2020</b> , 40, 289-303	1
185	Applying surface-based morphometry to study ventricular abnormalities of cognitively unimpaired subjects prior to clinically significant memory decline. <b>2020</b> , 27, 102338	7
184	Treatment of Alzheimer's Disease and Blood-Brain Barrier Drug Delivery. <b>2020</b> , 13,	29
183	Acute targeting of pre-amyloid seeds in transgenic mice reduces Alzheimer-like pathology later in life. <b>2020</b> , 23, 1580-1588	23
182	Clearance of interstitial fluid (ISF) and CSF (CLIC) group-part of Vascular Professional Interest Area (PIA): Cerebrovascular disease and the failure of elimination of Amyloid- $\beta$ from the brain and retina with age and Alzheimer's disease-Opportunities for Therapy. <b>2020</b> , 12, e12053	22
181	Functional Evolving Patterns of Cortical Networks in Progression of Alzheimer's Disease: A Graph-Based Resting-State fMRI Study. <b>2020</b> , 2020, 7839536	1

180	Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval. <b>2020</b> , 12, 95	85
179	Tumefactive Primary Central Nervous System Vasculitis: Imaging Findings of a Rare and Underrecognized Neuroinflammatory Disease. <b>2020</b> , 41, 2075-2081	6
178	Oral Health and Care for Elderly People with Alzheimer's Disease. <b>2020</b> , 17,	8
177	Vaccination against $\beta$ Amyloid as a Strategy for the Prevention of Alzheimer's Disease. <b>2020</b> , 9,	4
176	Symptomatic amyloid-related imaging abnormalities in an APOE $\epsilon$ / $\epsilon$ patient treated with aducanumab. <b>2020</b> , 12, e12101	12
175	Progress toward Alzheimer's disease treatment: Leveraging the Achilles' heel of A $\beta$ ligomers?. <b>2020</b> , 29, 1748-1759	21
174	Translational Scoring of Candidate Treatments for Alzheimer's Disease: A Systematic Approach. <b>2020</b> , 49, 22-37	4
173	Effect of apolipoprotein E $\epsilon$ allele on the progression of cognitive decline in the early stage of Alzheimer's disease. <b>2020</b> , 6, e12007	5
172	To Keto or Not to Keto? A Systematic Review of Randomized Controlled Trials Assessing the Effects of Ketogenic Therapy on Alzheimer Disease. <b>2020</b> , 11, 1583-1602	16
171	Development of the clinical candidate PBD-C06, a humanized pGlu3-A $\beta$ specific antibody against Alzheimer's disease with reduced complement activation. <b>2020</b> , 10, 3294	8
170	Immunotherapies for Aging-Related Neurodegenerative Diseases-Emerging Perspectives and New Targets. <b>2020</b> , 17, 935-954	15
169	Learning from amyloid trials in Alzheimer's disease. A virtual patient analysis using a quantitative systems pharmacology approach. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, 862-872	1.2 9
168	Passive anti-amyloid immunotherapy for Alzheimer's disease. <b>2020</b> , 33, 284-291	23
167	Genetic testing for neurodegenerative diseases: Ethical and health communication challenges. <b>2020</b> , 141, 104871	9
166	Ultra-High Field MRI in Alzheimer's Disease: Effective Transverse Relaxation Rate and Quantitative Susceptibility Mapping of Human Brain In Vivo and Ex Vivo compared to Histology. <b>2020</b> , 73, 1481-1499	5
165	Low-Dose Phosphodiesterase III Inhibitor Reduces the Vascular Amyloid Burden in Amyloid- $\beta$ Protein Precursor Transgenic Mice. <b>2020</b> , 21,	3
164	A practical approach to the management of cerebral amyloid angiopathy. <b>2021</b> , 16, 356-369	7
163	Drug Development for Psychotropic, Cognitive-Enhancing, and Disease-Modifying Treatments for Alzheimer's Disease. <b>2021</b> , 33, 3-13	5



162	Critical thinking on amyloid-beta-targeted therapy: challenges and perspectives. <b>2021</b> , 64, 926-937	2
161	Applications of focused ultrasound in the brain: from thermoablation to drug delivery. <b>2021</b> , 17, 7-22	49
160	Aducanumab: Appropriate Use Recommendations. <b>2021</b> , 8, 398-410	26
159	Association of naturally occurring antibodies to $\beta$ Amyloid with cognitive decline and cerebral amyloidosis in Alzheimer's disease. <b>2021</b> , 7,	8
158	Private payer coverage policies for ApoE-e4 genetic testing. <b>2021</b> , 23, 614-620	2
157	Anti-dementia Medication. <b>2021</b> , 73-104	
156	Immunotherapy for Alzheimer's Disease: Current Scenario and Future Perspectives. <b>2021</b> , 8, 534-551	1
155	APOE immunotherapy reduces cerebral amyloid angiopathy and amyloid plaques while improving cerebrovascular function. <b>2021</b> , 13,	23
154	Automated detection of cerebral microbleeds on T2*-weighted MRI. <b>2021</b> , 11, 4004	6
153	(Dys)regulation of Synaptic Activity and Neurotransmitter Release by $\beta$ Amyloid: A Look Beyond Alzheimer's Disease Pathogenesis. <b>2021</b> , 14, 635880	1
152	Cerebral microbleeds: from depiction to interpretation. <b>2021</b> ,	17
151	Association of Genotype With Heterogeneity of Cognitive Decline Rate in Alzheimer Disease. <b>2021</b> , 96, e2414-e2428	11
150	The Forgetful Golfer. <b>2021</b> , 26-29	
149	Uses of Human MR and PET Imaging in Research of Neurodegenerative Brain Diseases. <b>2021</b> , 18, 661-672	1
148	The Use, Standardization, and Interpretation of Brain Imaging Data in Clinical Trials of Neurodegenerative Disorders. <b>2021</b> , 18, 686-708	4
147	Effect of Sodium Benzoate on Cognitive Function Among Patients With Behavioral and Psychological Symptoms of Dementia: Secondary Analysis of a Randomized Clinical Trial. <b>2021</b> , 4, e216156	10
146	Cerebral Amyloid Angiopathy Burden and Cerebral Microbleeds: Pathological Evidence for Distinct Phenotypes. <b>2021</b> , 81, 113-122	2
145	Cerebral amyloid angiopathy and related inflammatory disorders. <b>2021</b> , 424, 117425	5

144	Donanemab in Early Alzheimer's Disease. <b>2021</b> , 384, 1691-1704		176
143	Prevalence of cerebral amyloid angiopathy: A systematic review and meta-analysis. <i>Alzheimer's and Dementia</i> , <b>2021</b> ,	1.2	16
142	Bayes analysis supports null hypothesis of anti-amyloid beta therapy in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2021</b> , 17, 1051-1055	1.2	5
141	Cortical Thickness and Its Association with Clinical Cognitive and Neuroimaging Markers in Cerebral Amyloid Angiopathy. <b>2021</b> , 81, 1663-1671		4
140	Clinical Efficacy, Drug Safety, and Surrogate Endpoints: Has Aducanumab Met All of Its Expectations?. <b>2021</b> , 97, 517-518		8
139	Event-related brain potential indexes provide evidence for some decline in healthy people with subjective memory complaints during target evaluation and response inhibition processing. <b>2021</b> , 182, 107450		2
138	Passive immunotherapy with a novel antibody against 3pE-modified A $\beta$ demonstrates potential for enhanced efficacy and favorable safety in combination with BACE inhibitor treatment in plaque-depositing mice. <b>2021</b> , 154, 105365		3
137	Donanemab removes Alzheimer's plaques: what is special about its target?. <b>2021</b> , 2, e395-e396		0
136	Innovative treatment targeting gangliosides aimed at blocking the formation of neurotoxic $\beta$ synuclein oligomers in Parkinson's disease. <b>2021</b> , 1		7
135	Effects of monoclonal antibodies against amyloid- $\beta$ on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer's disease. <b>2021</b> , 68, 101339		24
134	Amyloid-Targeting Drugs for the Treatment of Alzheimer Disease. <b>2021</b> , 39, 134-140		0
133	Predicting Brain Amyloid Using Multivariate Morphometry Statistics, Sparse Coding, and Correntropy: Validation in 1,101 Individuals From the ADNI and OASIS Databases. <b>2021</b> , 15, 669595		3
132	FEDERATED MORPHOMETRY FEATURE SELECTION FOR HIPPOCAMPAL MORPHOMETRY ASSOCIATED BETA-AMYLOID AND TAU PATHOLOGY.		0
131	Letter to the editor: Serum anti-A $\beta$ antibodies in cerebral amyloid angiopathy. <b>2021</b> , 20, 102870		0
130	Can we learn lessons from the FDA's approval of aducanumab?. <b>2021</b> , 17, 715-722		17
129	Spontaneous ARIA-like Events in Cerebral Amyloid Angiopathy-Related Inflammation: A Multicenter Prospective Longitudinal Cohort Study. <b>2021</b> , 97, e1809-e1822		9
128	Type 2 Diabetes, Glycemia, and Brain Health: The Complexity of Causality. <b>2021</b> , 70, 2187-2189		
127	Cerebral amyloid angiopathy related inflammation: A little known but not to be underestimated disease. <b>2021</b> , 16, 2514-2521		0

126	Citrullination of Amyloid- $\beta$ Peptides in Alzheimer's Disease. <b>2021</b> , 12, 3719-3732	2
125	Amyloid- $\beta$ and Synuclein Immunotherapy: From Experimental Studies to Clinical Trials. <b>2021</b> , 15, 733857	8
124	Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease. <b>2021</b> , 96, e1632-e1645	4
123	Safety, tolerability, and pharmacokinetics of allopregnanolone as a regenerative therapeutic for Alzheimer's disease: A single and multiple ascending dose phase 1b/2a clinical trial. <b>2020</b> , 6, e12107	7
122	Transcranial optical imaging reveals a pathway for optimizing the delivery of immunotherapeutics to the brain. <b>2018</b> , 3,	37
121	Investigating interventions in Alzheimer's disease with computer simulation models. <b>2013</b> , 8, e73631	23
120	The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations. <b>2014</b> , 1, 181-202	39
119	The Future of Anti-Amyloid Trials. <b>2020</b> , 7, 146-151	20
118	A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Safety, Pharmacokinetics, and Biomarker Results of Subcutaneous Bapineuzumab in Patients with mild to moderate Alzheimer's disease. <b>2016</b> , 54, 1509-1519	13
117	Novel strategies for Alzheimer's disease treatment: An overview of anti-amyloid beta monoclonal antibodies. <b>2016</b> , 48, 629-636	43
116	An update on clinical trials targeting human tauopathies. <b>2017</b> , 2, 66	5
115	An Alternate View of Neuroprotection with Peptides in Alzheimer's Disease.	1
114	Autoantibodies in Alzheimer's disease: potential biomarkers, pathogenic roles, and therapeutic implications. <b>2016</b> , 30, 361-372	46
113	Disclosing Genetic Risk of Alzheimer's Disease to Cognitively Unimpaired Older Adults: Findings from the Study of Knowledge and Reactions to APOE Testing (SOKRATES II). <b>2021</b> , 84, 1015-1028	2
112	Aducanumab (Marketed as Aduhelm) Approval Is Likely Based on Misinterpretation of PET Imaging Data. <b>2021</b> ,	5
111	Hope for Catching Alzheimer's Early. <b>2012</b> , 17, 20-22	
110	Alzheimer's Disease Mortality and Patient Retention in Clinical Trials. <b>2014</b> , 179-195	
109	AI Imaging in Aging, Alzheimer's Disease and Other Neurodegenerative Conditions. <b>2014</b> , 213-254	

108 A Rapidly Progressive Dementia. **2015**, 1-7

107 Dementia treatment versus prevention. **2019**, 21, 43-51

7

106 Alzheimer's disease and its current treatments; Is there a possibility for a cure?. **2019**, 5, 013-019

2

105 Gene Therapy Strategy for Alzheimer's and Parkinson's Diseases Aimed at Preventing the Formation of Neurotoxic Oligomers in SH-SY5Y Cells. **2021**, 22,

1

104 Immunotherapy Targeting Amyloid- $\beta$  Peptides in Alzheimer's Disease. 23-49

1

103 The Role of Clinical Trials in Preclinical Alzheimer's Disease Drug Development Programs. **2020**, 7, 288-290

0

102 Robust Biomarkers: Methodologically Tracking Causal Processes in Alzheimer's Measurement. **2020**, 289-318

1

101 Pharmacogenomic approaches to the treatment of sporadic Alzheimer's disease. **2020**, 81-94

100 Neuropathology of Alzheimer's Disease. **2021**,

11

99 A novel hybrid protein promotes A $\beta$  clearance and reduces inflammatory response through MerTK.

0

98 Distinct serum anti-A $\beta$  antibody patterns in hemorrhagic and inflammatory cerebral amyloid angiopathy manifestations.

97 Predicting Brain Amyloid using Multivariate Morphometry Statistics, Sparse Coding, and Correntropy: Validation in 1,101 Individuals from the ADNI and OASIS Databases.

1

96 A $\beta$  imaging in Aging, Alzheimer's Disease, and Other Neurodegenerative Conditions. **2021**, 283-343

95 [The future of dementia prevention and treatment strategies]. **2020**, 57, 374-396

94 Advances in designs for Alzheimer's disease clinical trials. **2012**, 1, 205-16

22

93 New treatment strategies for Alzheimer's disease: is there a hope?. **2013**, 138, 449-60

20

92 L-3-n-butylphthalide improves cognitive impairment of APP/PS1 mice by BDNF/TrkB/PI3K/AKT pathway. **2014**, 7, 1706-13

25

91 Intense Focus Yet Many Setbacks for Alzheimer's Disease Drug Development. **2018**, 43, 234-248

90	Editorial: Targets for Disease-Modifying Therapies in Alzheimer's Disease, Including Amyloid and Tau Protein. <b>2021</b> , 27, e934077	0
89	Emerging technologies and their impact on regulatory science. <b>2021</b> , 15353702211052280	3
88	Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease. <b>2021</b> ,	36
87	Federated Morphometry Feature Selection for Hippocampal Morphometry Associated Beta-Amyloid and Tau Pathology.. <b>2021</b> , 15, 762458	1
86	Prenatal and Postnatal Pharmacotherapy in Down Syndrome: The Search to Prevent or Ameliorate Neurodevelopmental and Neurodegenerative Disorders.. <b>2022</b> , 62, 211-233	0
85	Vessels Sing Their ARIAs: The Role of Vascular Amyloid in the Age of Aducanumab.. <b>2022</b> , 53, 298-302	0
84	Histopathological correlates of haemorrhagic lesions on magnetic resonance imaging in immunized Alzheimer's disease cases.. <b>2022</b> , 4, fcac021	0
83	Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer's Disease Treated with Anti-Amyloid Beta Therapy.. <b>2022</b> , 9, 211-220	1
82	White matter edematous change with moderate vascular lesions in pretreated acute stage of leukoencephalopathy with cerebral amyloid angiopathy.. <b>2022</b> ,	
81	Amyloid-Related Imaging Abnormalities and Amyloid-Targeting Antibodies: A Systematic Review.. <b>2022</b> ,	4
80	Disease Modeling and Model-Based Meta-Analyses to Define a New Direction for a Phase III Program of Gantenerumab in Alzheimer's Disease.. <b>2022</b> ,	0
79	Efficacy and Safety of Probiotics for the Treatment of Alzheimer's Disease, Mild Cognitive Impairment, and Parkinson's Disease: A Systematic Review and Meta-Analysis.. <b>2022</b> , 14, 730036	1
78	Neuropathology of Vascular Brain Health: Insights From Ex Vivo Magnetic Resonance Imaging-Histopathology Studies in Cerebral Small Vessel Disease.. <b>2022</b> , STROKEAHA121032608	3
77	Does the FDA-approved Alzheimer drug aducanumab have a place in the Australian pharmacopoeia?. <b>2022</b> ,	1
76	Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease.. <b>2022</b> , 9, 197-210	7
75	Aducanumab: Appropriate Use Recommendations Update.. <b>2022</b> , 9, 221-230	2
74	New Perspectives for Treatment in Alzheimer's Disease. <b>2022</b> , 199-225	
73	Aducanumab Use in Symptomatic Alzheimer Disease Evidence in Focus: Report of the AAN Guidelines Subcommittee.. <b>2022</b> ,	4

72	The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics.. <b>2022,</b>		24
71	2022 Alzheimer's disease facts and figures.. <i>Alzheimer's and Dementia</i> , <b>2022,</b>	1.2	95
70	Alzheimer's Disease Drug Development: A Research and Development Ecosystem. <b>2022,</b> 1-24		1
69	Safety and Efficacy of Monoclonal Antibodies for Alzheimer's Disease: A Systematic Review and Meta-Analysis of Published and Unpublished Clinical Trials.. <b>2022,</b>		3
68	Amyloid-Related Imaging Abnormalities With Anti-amyloid Antibodies for the Treatment of Dementia Due to Alzheimer's Disease.. <b>2022,</b> 13, 862369		1
67	Brain Imaging for Alzheimer's Disease Clinical Trials. <b>2022,</b> 375-394		
66	[Causal treatment of Alzheimer's disease: amyloid antibodies].. <b>2022,</b> 1		
65	Results and insights from a phase I clinical trial of Lomecel-B for Alzheimer's disease.. <i>Alzheimer's and Dementia</i> , <b>2022,</b>	1.2	1
64	Preclinical Longitudinal In Vivo Biomarker Platform for Alzheimer's Disease Drug Discovery. <b>2022,</b> 106-122		
63	Development of Fluid Biomarkers for Alzheimer's Disease. <b>2022,</b> 361-374		
62	Practical Considerations in the Administration of Aducanumab for the Neurologist. 10.1212/CPJ.0000000000001144		
61	Predicting Tau Accumulation in Cerebral Cortex with Multivariate MRI Morphometry Measurements, Sparse Coding, and Correntropy.. <b>2021,</b> 12088,		1
60	Peripheral Pathways to Neurovascular Unit Dysfunction, Cognitive Impairment, and Alzheimer's Disease.. <b>2022,</b> 14, 858429		0
59	Donanemab detects a minor fraction of amyloid- $\beta$ plaques in post-mortem brain tissue of patients with Alzheimer's disease and Down syndrome.. <b>2022,</b> 143, 601		1
58	PSEN1 G417S mutation in a Chinese pedigree causing early-onset parkinsonism with cognitive impairment.. <b>2022,</b> 115, 70-76		
57	The Patient Voice: Exploring Treatment Preferences in Participants with Mild Cognitive Concerns to Inform Regulatory Decision Making.. <b>2022,</b>		
56	Table_1.DOCX. <b>2018,</b>		
55	Disease-Modifying Therapies for Alzheimer's Disease: More Questions than Answers.. <b>2022,</b> 1		2

54	Vascular cognitive impairment and dementia: An early career researcher perspective.. <b>2022</b> , 14, e12310	0
53	Investigating the Effect of Tau Deposition and Apoe on Hippocampal Morphometry in Alzheimer's Disease: A Federated Chow Test Model. <b>2022</b> ,	
52	Therapeutic news in Alzheimer's disease: Soon a disease-modifying therapy?. <b>2022</b> ,	0
51	Impact of Cerebral Amyloid Angiopathy in Two Transgenic Mouse Models of Cerebral Amyloidosis: A Neuropathological Study.. <b>2022</b> , 23,	0
50	The Current Landscape of Prevention Trials in Dementia.. <b>2022</b> ,	0
49	Role of Aducanumab in the Treatment of Alzheimer's Disease: Challenges and Opportunities. Volume 17, 797-810	6
48	Amyloid-Related Imaging Abnormalities and Other MRI Findings in a Cognitively Unimpaired Population With and Without Cerebral Amyloid.	
47	Future Directions in Molecular Imaging of Neurodegenerative Disorders. <b>2022</b> , 63, 68S-74S	2
46	In silico exploration of amyloid-related imaging abnormalities in the gantenerumab open-label extension trials using a semi-mechanistic model. <b>2022</b> , 8,	0
45	Physiological Roles of Monomeric Amyloid- $\beta$ and Implications for Alzheimer's Disease Therapeutics. <b>2022</b> , 31, 65-88	3
44	Potential Eligibility for Aducanumab Therapy in an Irish Specialist Cognitive Service - Utilising CSF Biomarkers and Appropriate Use Criteria.	
43	Symptomatic and Disease-Modifying Therapy Pipeline for Alzheimer's Disease: Towards a Personalized Polypharmacology Patient-Centered Approach. <b>2022</b> , 23, 9305	0
42	Amyloid-Related Imaging Abnormalities with Emerging Alzheimer Disease Therapeutics: Detection and Reporting Recommendations for Clinical Practice.	0
41	Amyloid-related imaging abnormalities (ARIA).	
40	The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer's disease.	2
39	Association of Microglial Activation With Spontaneous ARIA-E and Cerebrospinal Fluid Levels of Anti-A Autoantibodies. 10.1212/WNL.0000000000200892	1
38	Designing the next-generation clinical care pathway for Alzheimer's disease. <b>2022</b> , 2, 692-703	3
37	High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects. <b>2022</b> ,	1

36	Cognitive Resilience in Brain Health and Dementia Research. <b>2022</b> , 1-13	1
35	Blood-brain barrier leakage and perivascular inflammation in cerebral amyloid angiopathy.	0
34	Aducanumab: a review of the first approved amyloid-targeting antibody for Alzheimer's disease.	0
33	PBPK model for antibody disposition in mouse brain: validation using large-pore microdialysis data.	0
32	Amyloid-related imaging abnormalities in the DIAN-TU -001 trial of gantenerumab and solanezumab: lessons from a trial in dominantly inherited Alzheimer disease.	0
31	Disclosing Individual Results in Dementia Research: A Proposed Study Participant's Bill of Rights. <b>2022</b> , 1-8	1
30	Detection of Cerebral Microbleeds in MR Images Using a Single-Stage Triplanar Ensemble Detection Network (TPE-Det).	0
29	Enhanced delivery of antibodies across the blood-brain barrier via TEMs with inherent receptor-mediated phagocytosis. <b>2022</b> ,	1
28	Vascular Considerations for Amyloid Immunotherapy. <b>2022</b> , 22, 709-719	0
27	Amyloid-Related Imaging Abnormalities: An Update.	0
26	High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 2: putative scenarios and timeline in case of approval, recommendations for use, implementation, and ethical considerations in France. <b>2022</b> ,	0
25	Subcortical signal alteration of corticospinal tracts. A radiologic manifestation of ARIA: A case report. <b>2023</b> , 18, 275-279	0
24	ApoE in Alzheimer's disease: pathophysiology and therapeutic strategies. <b>2022</b> , 17,	4
23	Current and Future Trends in Biomarkers for the Early Detection of Alzheimer's Disease in Asia: Expert Opinion. 1-12	0
22	Magnetic Resonance Imaging in Pharmaceutical Safety Assessment. <b>2022</b> , 1-19	0
21	Comparing ARIA-E severity scales and effects of treatment management thresholds. <b>2022</b> , 14,	0
20	Improved Prediction of Amyloid- and Tau Burden Using Hippocampal Surface Multivariate Morphometry Statistics and Sparse Coding. <b>2022</b> , 1-15	0
19	Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer's disease. <b>2022</b> , 14,	1



18	Cerebral Superficial Siderosis.	0
17	Capillary angiopathy and aquaporin-4 after A $\beta$ immunisation in Alzheimer's disease [potential relevance to Amyloid-Related Imaging Abnormalities.	0
16	N,N-Dimethylacetamide Targets Neuroinflammation in Alzheimer's Disease in In-vitro and Ex-vivo Models.	0
15	Alignment of Human Aquaporin 4 and beta-amyloid proteins may indicate involvement of beta-amyloid in prevention of brain edema.	0
14	Role of Inflammatory Processes in Hemorrhagic Stroke.	0
13	A $\beta$ 2 oligomer-specific antibody ALZ-201 reduces the neurotoxicity of Alzheimer's disease brain extracts. <b>2022</b> , 14,	0
12	Lecanemab for Alzheimer's disease: new hope or another false dawn?. <b>2023</b> , 27, 4-6	0
11	Anti-amyloid antibody therapies in Alzheimer's disease.	1
10	Targeting the Brain with Single-Domain Antibodies: Greater Potential Than Stated So Far?. <b>2023</b> , 24, 2632	0
9	Lecanemab (BAN2401): an antiBeta-amyloid monoclonal antibody for the treatment of Alzheimer disease. <b>2023</b> , 32, 89-94	0
8	Study on the Effect of 40 Hz Non-Invasive Light Therapy System. A Protocol for a Randomized, Double-Blinded, Placebo-Controlled Clinical Trial..	0
7	Advertisement by medical facilities as an opportunity of APOE genetic testing in Japan: a website analysis.	0
6	ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease. <b>2023</b> , 9,	0
5	Management of Alzheimer's disease in the next ten years. <b>2023</b> , 100,	0
4	Clinical Management in Alzheimer's Disease in the Era of Disease-Modifying Therapies. <b>2023</b> , 25, 121-133	0
3	Alignment of human aquaporin 4 and $\beta$ amyloid proteins may indicate involvement of $\beta$ amyloid in brain water homeostasis and prevention of brain edema.	0
2	Circulating exosomes from Alzheimer's disease suppress VE-cadherin expression and induce barrier dysfunction in recipient brain microvascular endothelial cell.	0
1	Gadolinium-based imaging of the blood brain barrier and brain waste clearance pathways. <b>2023</b> , 143-172	0

